Verastem (VSTM) News Today $5.22 -0.03 (-0.48%) As of 11:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Verastem: The Market Is Ignoring The ProgressJuly 16 at 8:42 AM | seekingalpha.comVerastem stock rises after LGSOC treatment data published in medical ...July 13, 2025 | investing.comVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial ...July 11, 2025 | gurufocus.comVerastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock NewsJuly 11, 2025 | gurufocus.comVerastem stock rises after LGSOC treatment data published in medical journalJuly 11, 2025 | in.investing.comVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical OncologyJuly 11, 2025 | businesswire.comVerastem, Inc. (VSTM) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 8, 2025 | businesswire.comBTIG Remains a Buy on Verastem (VSTM)July 4, 2025 | theglobeandmail.comVerastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer TreatmentJuly 4, 2025 | tipranks.comVerastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian CancerJune 30, 2025 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from BrokeragesJune 28, 2025 | marketbeat.comVerastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related CancersJune 26, 2025 | seekingalpha.comFY2025 EPS Estimates for Verastem Cut by Cantor FitzgeraldJune 26, 2025 | marketbeat.comVerastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - MorningstarJune 26, 2025 | morningstar.comMRoyal Bank Of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock PriceJune 25, 2025 | marketbeat.comInsider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)June 24, 2025 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 SharesJune 24, 2025 | marketbeat.comDan Paterson Sells 17,808 Shares of Verastem, Inc. (NASDAQ:VSTM) StockJune 24, 2025 | marketbeat.comVerastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid TumorsJune 24, 2025 | businesswire.comVerastem’s SWOT analysis: biotech stock poised for growth amid challengesJune 15, 2025 | investing.comVerastem reports promising cancer drug trial resultsJune 3, 2025 | investing.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 3, 2025 | businesswire.comVerastem’s Promising Clinical Advances and Strategic Developments Justify Buy RatingJune 3, 2025 | tipranks.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from BrokeragesJune 3, 2025 | marketbeat.comVerastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns BullishJune 2, 2025 | msn.comVerastem Announces Strategic Plans in Investor WebcastJune 2, 2025 | tipranks.comWhat's Going On With Verastem Oncology Stock On Monday?June 2, 2025 | benzinga.comVerastem, Inc. (NASDAQ:VSTM) Short Interest UpdateJune 2, 2025 | marketbeat.comVerastem Announces Promising Phase 1 Study ResultsJune 2, 2025 | tipranks.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 2, 2025 | businesswire.comInvestors Buy Large Volume of Verastem Call Options (NASDAQ:VSTM)May 31, 2025 | marketbeat.comVerastem Oncology to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | businesswire.comNorthern Trust Corp Boosts Holdings in Verastem, Inc. (NASDAQ:VSTM)May 28, 2025 | marketbeat.com723,806 Shares in Verastem, Inc. (NASDAQ:VSTM) Bought by Woodline Partners LPMay 27, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New $387,000 Investment in Verastem, Inc. (NASDAQ:VSTM)May 27, 2025 | marketbeat.comVerastem’s SWOT analysis: biotech firm’s stock poised for growth amid challengesMay 23, 2025 | investing.comVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline ...May 23, 2025 | finance.yahoo.comVerastem announces positive Phase 1/2 safety and efficacy results in PDACMay 23, 2025 | finance.yahoo.comVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal AdenocarcinomaMay 22, 2025 | businesswire.comSoleus Capital Management L.P. Reduces Stock Position in Verastem, Inc. (NASDAQ:VSTM)May 21, 2025 | marketbeat.comInsider Selling: Verastem, Inc. (NASDAQ:VSTM) CFO Sells 11,143 Shares of StockMay 21, 2025 | insidertrades.comTempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination TreatmentMay 20, 2025 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Shares Sold by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Takes $187,000 Position in Verastem, Inc. (NASDAQ:VSTM)May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 177,855 Shares of Verastem, Inc. (NASDAQ:VSTM)May 15, 2025 | marketbeat.comVerastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business UpdatesMay 13, 2025 | businesswire.comVerastem (NASDAQ:VSTM) Given New $14.00 Price Target at HC WainwrightMay 11, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by BrokeragesMay 11, 2025 | marketbeat.comBalyasny Asset Management L.P. Makes New $20.40 Million Investment in Verastem, Inc. (NASDAQ:VSTM)May 10, 2025 | marketbeat.com Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Media Mentions By Week VSTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼-0.210.96▲Average Medical News Sentiment VSTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼74▲VSTM Articles Average Week Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPKO Health News Geron News Regulus Therapeutics News Zenas BioPharma News Myriad Genetics News Lexicon Pharmaceuticals News Emergent Biosolutions News Rigel Pharmaceuticals News XOMA Royalty News Vanda Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
